Skip to main content

Month: March 2020

Aravive Announces Initiation of Investigator-Sponsored Phase 1/2 Study of AVB-500 in Combination with Avelumab in Patients with Advanced Urothelial Carcinoma (COAXIN)

HOUSTON, March 24, 2020 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that the first patient has been dosed in an investigator-sponsored Phase 1/2 clinical trial of the company’s GAS6/AXL inhibitor AVB-500 in combination with PD-L1 inhibitor avelumab in patients with advanced urothelial carcinoma (UC). The study is being led by Abhishek Tripathi, M.D., Assistant Professor of Medicine, Section of hematology/oncology at the University of Oklahoma Stephenson Cancer Center.“Locally advanced or metastatic urothelial carcinoma is an aggressive cancer with poor long-term survival,” said Dr. Tripathi. “Although immunotherapy results in durable responses in some patients, only a small proportion of patients respond and most eventually progress. Targeting additional mechanisms of immunosuppression...

Continue reading

PunaMusta Media -konserni aloittaa yt-neuvottelut lomautuksista

PUNAMUSTA MEDIA OYJ   SISÄPIIRITIETO    24.3.2020 KLO 14.00PunaMusta Media -konserni käynnistää yhteistoimintaneuvottelut koko henkilöstöään koskevista lomautuksista. Toimenpiteiden taustalla on maailmanlaajuisen koronaviruksen aiheuttamat äkilliset heikennykset mediamarkkinoiden ja painoliiketoimintojen eri segmenttien kysyntään. Yt-neuvottelut koskevat konsernin koko henkilöstöä.Yt-neuvottelujen ensisijaisena tavoitteena on varmistaa konsernin toimintaedellytysten säilyttäminen ja henkilöstön hyvinvoinnin turvaaminen.Neuvottelujen piirissä on noin 650 henkilöä. Mahdolliset sopeuttamistoimenpiteet on suunniteltu toteutettavaksi enintään 90 päivän lomautuksilla työntekijää kohden. Lisäksi neuvotteluissa tarkastellaan mahdollisuutta hakea ratkaisuja muiden työaikaan liittyvien toimenpiteiden kautta. Sopeuttamistoimenpiteissä otetaan huomioon...

Continue reading

TLSS Announces $1.7 Million in Debt Settlement Agreements

 Discounted Settlements Will Eliminate High-Interest Loans and Improve CashflowWEST PALM BEACH, FLORIDA, March 24, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Transportation and Logistics Systems, Inc. (OTC: TLSS), (“TLSS”, or the “Company”), a leading eCommerce fulfillment service provider, announced today that it has entered into several debt settlement agreements which, when finalized, will eliminate a total of approximately $1.7 million of high interest rate loans.The settlements include four (4) outstanding merchant credit advance loans in the aggregate amount of approximately $1,600,000 and a Senior Secured Promissory Note (“Secured Note”) in the approximate amount of $100,000 as well as the cancellation of 40,300 common stock warrants that were issued in connection with the Secured Note. TLSS will pay approximately...

Continue reading

ReWalk Letter to Shareholders on COVID-19 and the Potential Impact on Operations

MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, March 24, 2020 (GLOBE NEWSWIRE) — ReWalk Robotics Ltd. (Nasdaq: RWLK) a global leader in Exoskeleton technology for community use and rehabilitation centers, today issued the following letter to shareholders:To All Shareholders:The emerging coronavirus (COVID-19) outbreak represents a challenge to our community and all of our stakeholders.  This letter is an update on this situation as it pertains to ReWalk Robotics and our global operations.We fully support the efforts of all clinics and customers to manage this pandemic.  Our clinics are focused on managing the emergency and therefore have limited in-person contact and elective activities.  We encourage our home, community and clinic-based users of our products to follow the relevant local and national public health protocols...

Continue reading

OCEANFIRST FINANCIAL CORP. SCHEDULES INVESTOR CONFERENCE CALL

RED BANK, N.J., March 24, 2020 (GLOBE NEWSWIRE) — OceanFirst Financial Corp. (NASDAQ:OCFC), the holding company for OceanFirst Bank (the “Bank”), today announced that management will host a conference call for investors on March 24, 2020 at 4:30 p.m. Eastern Time.  Management will discuss the Bank’s preparations and response to COVID-19 and other related matters.  A presentation referenced by management will be posted at www.oceanfirst.com in the Investor Relations section prior to the call.The direct dial number for the call is 1-888-338-7143.  For those unable to participate in the conference call, a replay will be available.  To access the replay, dial 1-877-344-7529, Replay Conference Number 10141079 from one hour after the end of the call until June 24, 2020.Forward-Looking StatementsIn addition to historical information, this...

Continue reading

Menlo Therapeutics Appoints Andrew Saik as Chief Financial Officer

BRIDGEWATER, N.J., March 24, 2020 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, appointed Andrew Saik as Chief Financial Officer and Treasurer, effective March 23, 2020. Mr. Saik will report to David Domzalski, Chief Executive Officer, and will be responsible for leading the Company’s global finance operations, including, financial planning and analysis, investor relations, accounting, tax, treasury, supply chain and information technology. He will be based at the Company’s headquarters in Bridgewater, New Jersey.“Andrew is an accomplished CFO and brings a wealth of experience to the senior management team at Menlo,” said David Domzalski, Chief Executive Officer...

Continue reading

LexaGene Appoints Steven Armstrong to Senior Director of Operations

BEVERLY, Mass., March 24, 2020 (GLOBE NEWSWIRE) — LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, today announced the appointment of Mr. Steven Armstrong to the role of Senior Director of Operations to oversee the Company’s submission for FDA Emergency Use Authorization of its commercial technology and other regulatory approvals, as well as to institute quality systems for manufacturing.Dr. Jack Regan, LexaGene’s CEO and Founder states, “I’m thrilled that Mr. Armstrong has joined the team to guide us during this next phase of commercial manufacturing. We are taking every measure to hasten our readiness for FDA approval, not only for our commercial analyzer, but also for the test chemistry of our...

Continue reading

CONSTELLATION BRANDS REINFORCES STRENGTH OF ITS BREWERY PRODUCTION FOOTPRINT IN MEXICO

VICTOR, N.Y., March 24, 2020 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, today responded to the outcome of a recent public consultation in Mexicali, Baja California (Mexico) which voiced opposition to the company’s plans to build a new brewery in the city.“We will continue working with local authorities, government officials and members of the community on next steps related to our brewery construction project in Mexicali and options elsewhere in Mexico,” said Bill Newlands, president and chief executive officer at Constellation Brands. “In the meantime, it’s important to note that we have ample capacity, based on current growth forecasts and production capabilities at our Nava brewery and soon to be completed expansion in Obregon, to continue fueling the growth of our...

Continue reading

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update

U.S. Food and Drug Administration allowed Black Diamond’s investigational new drug application for its lead product candidate BDTX-189 in December; Company initiated Phase 1/2 clinical trial and has subsequently started enrolling and dosing patientsCash and cash equivalents of $154.7 million as of December 31, 2019, together with net proceeds from initial public offering (IPO) of approximately $212.4 million, believed to be sufficient to fund anticipated operations into 2023 — $85.0 million Series C financing successfully completed in November 2019 — IPO completed in February 2020 raised approximately $231.3 million in gross proceedsCRISPR Therapeutics CEO Samarth Kulkarni, Ph.D., joined the Board of DirectorsCAMBRIDGE, Mass. and NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX),...

Continue reading

REVIVAL GOLD RESPONDS TO COVID-19 PANDEMIC, WITHDRAWS PUBLIC OFFERING AND ANNOUNCES $1 MILLION NON-BROKERED PRIVATE PLACEMENT FINANCING

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, March 24, 2020 (GLOBE NEWSWIRE) — Revival Gold Inc. (TSXV: RVG, OTCQB: RVLGF) (“Revival Gold” or the “Company”), a growth‐focused gold exploration and development company, announces the following in response to the developing COVID-19 pandemic:The safety of our employees and independent contractors is paramount. Revival Gold took steps to ensure its compliance with Health Canada and Centers for Disease Control & Prevention guidelines on February 27th, 2020 and subsequently directed employees and active independent contractors to work from home and eliminate all Company-related business travel. All key personnel are accounted for and in good health. As a result of turbulent market conditions, Revival Gold, in consultation...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.